Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 18/20 | 0.88 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.75 |
| ▸ | BAD | Q92934 | 2/20 | 0.75 |
| ▸ | BCL2 | P10415 | 1/20 | 0.75 |
| ▸ | PMAIP1 | Q13794 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23111137 | 0.95 | MCL1 (0.88) | MCL1BCL2L1BADBCL2PMAIP1 | |
| SCHEMBL22437311 | 0.94 | MCL1 (1.00) | MCL1BCL2L1BADBCL2PMAIP1 | |
| SCHEMBL22437411 | 0.94 | MCL1 (0.86) | MCL1BCL2L1BADBCL2PMAIP1 | |
| SCHEMBL19635904 | 0.94 | MCL1 (0.77) | MCL1BCL2L1BADBCL2PMAIP1 | |
| SCHEMBL23111360 | 0.94 | MCL1 (0.88) | MCL1BCL2L1BADBCL2PMAIP1 | |
| SCHEMBL23786350 | 0.92 | BAD (0.88) | MCL1BCL2L1BADBCL2PMAIP1 | |
| SCHEMBL19615277 | 0.91 | MCL1 (0.72) | MCL1BCL2L1BADBCL2PMAIP1 | |
| SCHEMBL23110793 | 0.90 | MCL1 (0.87) | MCL1BCL2L1BADBCL2PMAIP1 | |
| SCHEMBL23111367 | 0.89 | MCL1 (0.86) | MCL1BCL2L1BADBCL2PMAIP1 | |
| SCHEMBL23111237 | 0.89 | MCL1 (0.88) | MCL1BCL2L1BADBCL2PMAIP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3710449-B1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES AS MCL-1 INHIBITORS, FOR USE IN THE TREATMENT OF CANCER | BROAD INST INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11286263-B2 | Macrocyclic fluorine substituted indole derivatives | THE BROAD INSTITUTE, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-20210079018-A1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-03-18 | — | — | US | disclosed |
| US-9512104-B2 | Quinolone inhibitors of lipoprotein-associated phospholipase A2 | AUSPEX PHARMACEUTICALS, INC. (US) | 2016-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286263-B2 | Macrocyclic fluorine substituted indole derivatives | FOXM1, CCNT2, CCND2 | MCL1 34/4885BCL2L1 582/4885BAD 291/4885 |
| US-20210079018-A1 | MACROCYCLIC FLUORINE SUBSTITUTED INDOLE DERIVATIVES | FOXM1, CCNT2, CCND2 | MCL1 34/4885BCL2L1 582/4885BAD 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.